Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 51

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 51
---
 by and between the Company and PatentVest.

Pursuant to the Restricted Stock Agreement, the
Company agreed to include the Restricted Stock in any registration statement subsequently filed by the Company, to the extent a shelf
registration statement with respect to the Restricted Stock had not previously been filed.

Our shares of common stock are listed on the Nasdaq
Capital Market under the symbol “NDRA.”

<div align='center'>9

DESCRIPTION OF
PREFERRED STOCK WE MAY OFFER</div>

This section describes the general terms and provisions
of the preferred stock we may offer. This information may not be complete in all respects and is qualified entirely by reference to our
Fourth Amended and Restated Certificate of Incorporation, as amended, with respect to each series of preferred stock. The specific
terms of any series will be described in a prospectus supplement. Those terms may differ from the terms discussed below. Any series of
preferred stock we issue will be governed by our Fourth Amended and Restated Certificate of Incorporation, as amended, and by the certificate
of designations relating to that series. We will file the certificate of designations with the SEC and incorporate it by reference as
an exhibit to our registration statement at or before the time we issue any preferred stock of that series.

Authorized Preferred Stock

Our Certificate of Incorporation authorizes us
to issue 10,000,000 shares of preferred stock, par value $0.0001 per share. We have designated 10,000 shares of preferred stock as Series
A Convertible Preferred Stock (“Series A Preferred Stock”), 1,000 shares of preferred stock as Series B Convertible Preferred
Stock (“Series B Preferred Stock”) and 100,000 shares of preferred stock as Series C Preferred Stock (“Series C Preferred
Stock”) and the remainder of 9,889,000 shares remain authorized but undesignated. As of February 13, 2024, we had 34.976 shares
of Series A Preferred Stock and no shares of Series B Preferred Stock or Series C Preferred Stock issued and outstanding. Our authorized
but unissued shares of preferred stock are available for issuance without further action by our stockholders, unless such action is required
by applicable law or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded.

Our board of directors has the authority to issue
preferred stock in one or more series and to fix the designations, powers, rights, preferences, qualifications, limitations and restrictions
there